These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15156270)

  • 1. Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension-a case report.
    Younger JR; Lui CY
    Angiology; 2004; 55(3):341-4. PubMed ID: 15156270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
    Farber HW; Graven KK; Kokolski G; Korn JH
    J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of prostacyclin and its analogues in the treatment of cardiovascular disease.
    Fink AN; Frishman WH; Azizad M; Agarwal Y
    Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.
    Waxman AB
    Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epoprostenol in the treatment of portopulmonary hypertension].
    Culafić D; Culafić-Vojinović V; Jesić R
    Srp Arh Celok Lek; 2003; 131(5-6):271-4. PubMed ID: 14692137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report.
    Badalian SS; Silverman RK; Aubry RH; Longo J
    J Reprod Med; 2000 Feb; 45(2):149-52. PubMed ID: 10710749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
    Matthes J; Mathen F; Herzig S; Wassermann K
    Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostacyclin therapy for pulmonary arterial hypertension.
    Ruan CH; Dixon RA; Willerson JT; Ruan KH
    Tex Heart Inst J; 2010; 37(4):391-9. PubMed ID: 20844610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timeline of haemodynamic improvement with subcutaneous prostacyclin therapy in a patient with severe pulmonary arterial hypertension.
    Sadushi-Koliçi R; Perthold W; Fruhwald FM; Lang IM
    Eur J Clin Invest; 2008 Aug; 38(8):603-4. PubMed ID: 18573098
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
    Myers SA; Ahearn GS; Angelica Selim M; Tapson VF
    J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoprostenol-induced hypersplenism in portopulmonary hypertension.
    Touma W; Nayak RP; Hussain Z; Bacon BR; Kudva GC
    Am J Med Sci; 2012 Nov; 344(5):345-9. PubMed ID: 22227513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.
    Kesten S; Dainauskas J; McLaughlin V; Rich S
    Chest; 1999 Aug; 116(2):566-9. PubMed ID: 10453891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    Botney M
    N Engl J Med; 1998 Jun; 338(24):1773-4. PubMed ID: 9625639
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid development of severe interstitial pneumonia caused by epoprostenol in a patient with primary pulmonary hypertension.
    Morimatsu H; Goto K; Matsusaki T; Katayama H; Matsubara H; Ohe T; Morita K
    Anesth Analg; 2004 Oct; 99(4):1205-1207. PubMed ID: 15385376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy.
    Ogawa A; Matsubara H; Fujio H; Miyaji K; Nakamura K; Morita H; Saito H; Kusano KF; Emori T; Date H; Ohe T
    Circ J; 2005 Feb; 69(2):216-20. PubMed ID: 15671616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.